Healthcare & Life Sciences

Trans-septal Quilting Suturing vs Intranasal Silicone Splinting in Septoplasty

NIH ClinicalTrials.gov registered a randomized controlled trial (NCT07537920) comparing trans-septal quilting suturing versus intranasal silicone splinting following septoplasty in patients with deviated nasal septum. The study aims to identify which post-operative technique results in fewer adverse effects. Participants will be enrolled with an estimated completion date of April 2026.

Quadro-Iliac Plane Block vs Erector Spinae Plane Block After Total Hip Arthroplasty

NIH's ClinicalTrials.gov registered a new comparative clinical study (NCT07537036) evaluating the analgesic efficacy of Quadro-Iliac Plane Block versus Erector Spinae Plane Block in patients undergoing total hip arthroplasty. The interventional study will assign participants to receive one of two regional anesthesia techniques. This trial registration provides public transparency on ongoing medical research but does not establish regulatory compliance obligations.

Phase 4 Antihistamine Trial for HTR Prevention in 40 Children, NCT07536152

NIH registered a Phase 4 randomized, double-blinded, placebo-controlled clinical trial (NCT07536152) at a university hospital evaluating intravenous antihistamine (chlorpheniramine) versus placebo for prevention of blood transfusion-associated adverse reactions in 40 children undergoing elective congenital heart defect repair with blood-primed cardiopulmonary bypass. The study will randomly assign 20 patients per group to receive a single dose immediately after separation from bypass prior to protamine administration.

Prospective Longitudinal EVOH Renal Embolization Study in ADPKD

NIH has registered a prospective longitudinal observational study (NCT07535385) evaluating the radiological and clinical outcomes of renal embolization using ethylene-vinyl alcohol copolymer (EVOH) in dialysis patients with autosomal dominant polycystic kidney disease (ADPKD). The study aims to assess renal volume changes, complications, and prognostic factors in affected patients. Results may inform treatment strategies for ADPKD-related renal failure.

Phase 4 Cardiac Surgery Ketamine Anti-inflammatory Trial NCT07536633

NIH ClinicalTrials.gov registered a Phase 4 clinical trial (NCT07536633) investigating the anti-inflammatory effect of ketamine in cardiac surgery patients. The randomized controlled study will evaluate intraoperative ketamine administration (1 mg/kg induction plus 2.4 mg/kg/h maintenance infusion) versus control on inflammatory markers including neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and C-reactive protein. The trial targets adult cardiac surgery patients and will assess pain scores, hospital mortality, and morbidity outcomes.

Williams Syndrome iPSC Oligodendrocyte Study

NIH's ClinicalTrials.gov has registered NCT07537374, a case-control observational study examining oligodendrocyte lineage development in children with Williams syndrome using peripheral blood-derived iPSC models. The study plans to enroll 3 children with Williams syndrome and 3 healthy controls, with samples induced into neural progenitor cells and oligodendrocyte lineage cells for in vitro studies of myelin-related gene programs and developmental trajectories.

Phase 1/2a Trial of NWRD09 for Persistent HPV16 Infection in Female Participants

The NIH ClinicalTrials.gov registry has posted a new Phase 1/2a clinical trial (NCT07536282) evaluating NWRD09, an investigational drug, for the treatment of persistent HPV16 infection in female participants. The two-part study will assess safety, tolerability, immunogenicity, and efficacy while determining the maximum tolerated dose and recommended Phase 2 dose. Participants will receive either NWRD09 or placebo as part of the study design.

Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease - NCT07536490

The NIH National Library of Medicine registered an observational study (NCT07536490) on ClinicalTrials.gov investigating the relationship between sleep quality, cognitive function, and disease severity in individuals with Parkinson's disease. The single-session study will assess participants using standardized tools including the Stroop Test, Clock Drawing Test, Montreal Cognitive Assessment, Unified Parkinson's Disease Rating Scale, and Modified Hoehn and Yahr Scale. The study enrolls participants diagnosed with Parkinson Disease.

Lullabies and White Noise Breastfeeding Study

NIH registered clinical trial NCT07537218 on ClinicalTrials.gov. The randomized controlled experimental study examines the effect of lullabies and white noise on breastfeeding success in newborns. The study enrolled 160 newborns divided into four groups: female voice lullaby, male voice lullaby, white noise, and control, with data collected using the LATCH Breastfeeding Assessment Scale.

ESP Block Trial for Postoperative Spinal Pain Relief

NIH registered clinical trial NCT07537647, titled 'The Effect of Bilateral Erector Spina Plane Block on Postoperative Pain in Spinal Surgery.' The trial studies whether ultrasound-guided ESP block with bupivacaine reduces postoperative pain in patients undergoing lumbar spinal stabilization surgery. The study was registered on ClinicalTrials.gov and is listed as not yet recruiting with an estimated completion date of April 17, 2026.

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

NIH registered an observational clinical trial (NCT07535242) investigating whether serum biomarkers GFAP, NfL, and VEGF serve as indicators of clinical progression in progressive multiple sclerosis. The study aims to better understand MS pathophysiology through biomarker analysis. This registry entry provides transparency on ongoing research but imposes no regulatory obligations on affected parties.

Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease

NIH registered a retrospective cohort study (NCT07537829) on steatotic liver disease in elderly patients. The single-center observational study will analyze approximately 10,000 participants aged 60 and older from the Nanjing Elderly Steatotic Liver Disease Cohort to investigate liver-related and extrahepatic adverse outcomes. Risk prediction models will be developed using machine learning algorithms; no intervention is involved.

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07535632) at Zhongshan Hospital, Fudan University in China. The trial will study stereotactic body radiotherapy (SBRT) combined with sintilimab, bevacizumab, and TAS-102 as third-line therapy for 58 patients with recurrent or metastatic colorectal cancer. The 24-month study has a primary endpoint of progression-free survival.

High-flow Nasal Cannula Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema

NIH has registered Clinical Trial NCT07536477, a randomized controlled study evaluating High-flow Nasal Cannula Oxygen Therapy (HFNC) versus Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE). The single-center trial plans to enroll 168 participants, with an estimated completion date of April 17, 2026. HFNC is the sole intervention under investigation.

PD-1 Plus Lenvatinib vs Regorafenib for Unresectable Hepatocellular Carcinoma

NIH ClinicalTrials.gov registered a new Phase 2/3 clinical trial (NCT07537985) comparing the efficacy and safety of PD-1 inhibitor combined with Lenvatinib versus PD-1 inhibitor combined with Regorafenib for unresectable hepatocellular carcinoma (UHCC) after failure of first-line treatment with bevacizumab plus sintilimab. The study aims to provide evidence-based guidance for selecting optimal second-line treatment regimens. Estimated enrollment and completion date are listed in the registry.

Ego-Tucking: Exploring Psychological Mechanisms of Fo-xi Phenomenon Among University Students

The NIH registered observational study NCT07536711 on ClinicalTrials.gov examining psychological mechanisms, stress, and mental fatigue among university students. The cross-sectional study uses a structured questionnaire to explore individual experiences, family dynamics, and macro-social environments contributing to behavioral changes in academic and professional competition contexts.

Phase 2 Trial for Intestinal Fluid Reinfusion Prevention of Low Anterior Resection Syndrome

NIH registered a Phase 2 clinical trial (NCT07537998) on ClinicalTrials.gov to evaluate antegrade intestinal fluid reinfusion for prevention of low anterior resection syndrome in patients with prophylactic ileal stoma. The single-center, prospective randomized controlled trial will compare intestinal fluid infusion to potable water infusion in approximately 60 participants. Participants will receive the assigned intervention at 1 month post-rectal resection until ileostomy reversal and maintain symptom diaries.

Monocyte Ratios, APRs, and Sepsis ICU Study

NIH's ClinicalTrials.gov registered a new observational study (NCT07537179) examining whether monocyte distribution, monocyte-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio can serve as biomarkers in sepsis patients in the ICU. The study will enroll patients admitted to the ICU for sepsis or those who develop sepsis during hospitalization, comparing these ratios with conventional acute phase response biomarkers.

Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control

NIH ClinicalTrials.gov registered a clinical trial (NCT07535658) studying photolithography flat microstructure lenses for childhood myopia prevention and control. The randomized controlled trial will compare plano microstructure lenses with multi-point defocus design against Spectacle Lenses with Aspherical Lenslets (Essilor Stellest) in children over a 1-year period.

Observational Study of Language Reorganization in AVM Patients

NIH registered observational clinical trial NCT07537504 on ClinicalTrials.gov. The study investigates language function reorganization in patients with brain arteriovenous malformations (AVMs) involving language areas. Researchers will use multimodal MRI to examine functional remodeling, white matter pathway remodeling, and structural remodeling from multiple dimensions. The study aims to elaborate the role of the right cerebral hemisphere in reorganized language networks and interhemispheric interaction mechanisms.

At-Home taVNS for Neurorehabilitation in Parkinson's Disease

NIH registered a new clinical trial (NCT07536022) evaluating at-home transcutaneous auricular vagus nerve stimulation (taVNS) for neurorehabilitation in approximately 40 adults with Parkinson's Disease. The 8-week study will assess feasibility, tolerability, and preliminary efficacy of self-administered daily 1-hour taVNS sessions using a threshold-based individual dosing protocol. Secondary objectives include measuring changes in motor and non-motor symptoms and examining neural network connectivity via MRI.

Wildfire Smoke Lung Health Study, Canada, Asthma COPD

NIH registered a clinical trial (NCT07536178) titled 'Lungs on Fire' to study how wildfire smoke exposure contributes to long-term lung disease in susceptible populations. The controlled human exposure study will test varying concentrations of woodsmoke from Lodgepole Pine on participants with asthma, COPD, and lung cancer in Canada. The research aims to identify health impacts, vulnerable populations, and biological changes leading to chronic illness.

NAUTILUS Project Develops Mutation-Specific ASO for Syndromic Craniosynostoses

NIH ClinicalTrials.gov registered observational study NCT07535372 for the NAUTILUS project, developing ultra-personalized antisense oligonucleotide (ASO) therapeutics for syndromic craniosynostoses. The study targets rare genetic conditions including Crouzon, Saethre-Chotzen, Muenke, Pfeiffer, and Apert syndromes caused by FGFR1/2/3, TWIST1, and TCF12 variants. ASO design will be patient-tailored to silence gain-of-function alleles or restore expression in loss-of-function contexts.

Decision Aid Efficacy in Low Risk Thyroid Cancer

NIH ClinicalTrials.gov registered a clinical trial (NCT07536412) evaluating whether a decision aid pamphlet reduces decision anxiety and improves treatment decision readiness in low-risk thyroid cancer patients. The study will enroll patients diagnosed with differentiated thyroid cancer, papillary thyroid microcarcinoma, or papillary thyroid carcinoma to receive the decision aid before meeting with a surgeon. The intervention provides information about three treatment options (total thyroidectomy, partial thyroidectomy, or active surveillance) and questions for patients to ask their surgeon.

Ivonescimab With Dato-DXd or Osimertinib Phase 1

NIH ClinicalTrials.gov registered Phase 1 trial NCT07535437 evaluating ivonescimab in combination with Dato-DXd or osimertinib for treatment of EGFR-mutated non-small cell lung cancer. The dose-escalation study will assess safety and tolerability to determine optimal dosing. Participants with NSCLC harboring EGFR mutations will receive fixed-dose ivonescimab with escalating doses of either Dato-DXd or osimertinib.

Controllable Insertion Sleeve with Guide and Control Wires

USPTO granted Patent US12599749B2 to Kardion GmbH for a controllable insertion sleeve with a guide wire extending through a cavity in the sleeve wall and at least one control wire integrated into the sleeve wall to cause curvature. The patent, with 11 claims, covers CPC classifications A61M 25/0147 and related categories. Filing date was May 30, 2019 (Application No. 17056937).

US Patent 12599757B2 - Fabrication Method for Complex 3D Microscale Structures

The USPTO granted Patent 12599757B2 to The Charles Stark Draper Laboratory, Inc. on April 14, 2026, covering a bilayer mold fabrication method for forming polymer and metal microstructures. The invention enables creation of complex re-entrant 3D microscale structures using laser-etching of metallic foil and plastic elastic polymer materials. Six claims were granted.

Splitable Catheter Docking Station System and Method

USPTO granted patent US12599752B2 to Bard Access Systems, Inc. covering a splitable catheter docking station system for rapid insertion central catheters (RICC). The patent protects a two-step insertion system featuring a docking station that detaches from an introducer placement system, with design elements including guidewire hub, collapsible sterile barriers, and locking features to prevent premature advancement.

Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness in Transfused Recipients

USPTO granted patent US12599667B2 to BLOODWORKS for methods of preventing platelet alloimmunization and alloimmune platelet refractoriness in transfused recipients. The patent covers modifying donor whole blood or platelets prior to transfusion to prevent or reduce transfusion-associated complications. The patent includes 15 claims and was filed on September 28, 2022.

Composition Comprising Three-Dimensional Astrocyte Bundles and Methods of Making and Using

The USPTO granted Patent US12599670B2 to the Trustees of the University of Pennsylvania covering compositions comprising three-dimensional astrocyte bundles with bipolar and aligned astrocyte processes, methods of making such compositions through ex vivo machine-driven physical stretching or growth within hydrogel micro-columns, and methods of treating nervous system injury or degeneration by implanting the compositions. The patent contains 25 claims and lists D. Kacy Cullen as inventor.

Guidewire Assembly With Intertwined Core Wire, Acclarent, Inc.

USPTO granted patent US12599754B2 to Acclarent, Inc. for a guidewire assembly featuring a helical wire coil and a non-extensible core wire that is intertwined with the coil to inhibit longitudinal elongation. The patent, with 20 claims, was filed March 21, 2022 under Application No. 17699225.

Vascular Access Connector Support Device, Systems, and Methods

USPTO granted Patent US12599750B2 to Becton, Dickinson and Company for a vascular access connector support device. The patent covers a catheter system including a connector support device that is wedge-shaped to support the connector at an insertion angle. The patent names Jonathan Karl Burkholz, Curtis H. Blanchard, and Weston F. Harding as inventors.

Vascular Catheter and Method - US12599755B2

USPTO granted patent US12599755B2 to I-VASC S.R.L. for a vascular catheter featuring occlusion elements and an expandable balloon between them. The catheter handle includes dual pumping devices with synchronization capabilities for fluid management. The patent contains 17 claims covering the catheter shaft, balloon mechanism, pumping system, and control handle.

KARDIUM Catheter Safety Release System, US12599747B2, Issued Apr 14, 2026

USPTO granted patent US12599747B2 to KARDIUM INC. on April 14, 2026. The patent covers medical device systems including a catheter sheath and shaft with an end effector, featuring a control element that can be severed to facilitate removal from bodily cavities. The invention also includes a liquid entry port for expedited fluid provision to distal portions. The patent contains 22 claims.

Bard Access Systems Catheter Tip Patent US12599748B2

The USPTO granted patent US12599748B2 to Bard Access Systems, Inc. on April 14, 2026, covering a rapidly insertable central catheter with a single-piece catheter tip design featuring uniform and non-uniform tapered sections for tissue dilation. Inventors are Glade H. Howell and Juan Sepulveda, with 16 claims allowed and application filed December 6, 2022.

V-Wave Interatrial Shunt Patent US12599756B2 Granted April 14

USPTO granted patent US12599756B2 to V-Wave Ltd. covering interatrial shunt devices with in vivo adjustable dimensions. The patent includes 14 claims for a body with shape-memory material defining a passageway through a neck region between atria, where first and second regions are superelastic at body temperature and the neck region is malleable for flow adjustment.

ELTA Patent - Enzymatic ADP-ribose Labeling Methods

USPTO granted patent US12601734B2 to Johns Hopkins University covering ELTA (Enzymatic Labeling of Terminal ADP-ribose) technology for labeling free, protein-conjugated, or nucleic acid-conjugated ADP-ribose molecules at their 2'-OH termini. The patent contains 28 claims and covers applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.

Beta Ketoacyl Synthase IV Variants by CORBION BIOTECH

USPTO granted Patent US12600994B2 to CORBION BIOTECH, INC. covering non-natural variant β-ketoacyl-ACP synthase (KAS) IVa enzymes, polynucleotides encoding such variants, host cells expressing such variants, and oils and oil products produced by such cells. The patent names Joshua Ferreira, Janice Lau Wee, and Nien-Hsi Ko as inventors. Filing date was January 15, 2021, with 21 claims granted.

Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same

USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.

AB Enzymes Xylanase Variants - Patent US12600960B2

The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.

Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells

USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.

US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto

USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.

Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell

USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.

Multiplex Genome Editing of Immune Cells for Enhanced Functionality and Resistance to Suppressive Environment

The USPTO granted patent US12600944B2 to the Board of Regents, The University of Texas System covering methods for multiplex genome editing of immune cells, including disruption of multiple genes and insertion of chimeric antigen receptors at specific gene loci. The patent names Rafet Basar, Elizabeth Shpall, and Katy Rezvani as inventors and contains 14 claims. The filing date was November 27, 2019.

Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine

USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.

Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity

USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.

Low-Level Diode Laser Therapy for Osseointegration Around Delayed Dental Implants

NIH ClinicalTrials.gov has registered a new clinical study (NCT07536451) evaluating the efficacy of Low-Level Diode Laser Therapy (LLDLT) on enhancing osseointegration and peri-implant mucosal tissue around delayed dental implants. The study will compare dental implant placement with LLDL intervention against standard dental implant placement without laser therapy. No compliance obligations or regulatory actions are imposed by this registration.

Food is Medicine in Pediatric Patients With Diabetes

The NIH ClinicalTrials.gov registry has published a randomized controlled trial (NCT07535502) evaluating Food is Medicine Programming through medically tailored pre-packaged meals for pediatric patients with Type 1 Diabetes. The study will assess whether medically-tailored meals combined with nutrition counseling improves clinical outcomes, decreases healthcare utilization, and improves health-related quality of life in children and adolescents with diabetes and potential food security concerns.

Microgreens on Sleep Architecture, Athletes

NIH registered clinical trial NCT07537140 on ClinicalTrials.gov investigating the effects of microgreen consumption on sleep architecture in athletes. The study will assess sleep onset latency, total sleep time, sleep efficiency, and NREM/REM distribution. The trial lists cabbage as the control intervention and an oral microgreen cocktail as the experimental intervention, with an anticipated completion date of April 17, 2026.

Ivonescimab, Chemotherapy, and SRS for Non-Small Cell Lung Cancer Brain Metastases

The NIH National Library of Medicine registered a Phase 1 clinical trial (NCT07535463) on ClinicalTrials.gov testing ivonescimab in combination with standard chemotherapy and stereotactic radiosurgery for patients with non-small cell lung cancer that has spread to the brain. The study aims to establish the safe dosage of ivonescimab in this combination regimen and evaluate its effectiveness in treating brain metastases. The trial is listed as Phase 1, indicating an early-stage safety and dosing study.